Format

Send to

Choose Destination
Anticancer Drugs. 2007 Aug;18(7):831-4.

Medullary thyroid cancer treated by capecitabine.

Author information

1
Department of Medical Oncology, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France. labidi@lyon.fnclcc.fr

Abstract

Medullary thyroid carcinoma with distant metastases is generally incurable, with 20% overall survival at 10 years. The treatment goal is palliative. Chemotherapy has a limited role, with low response rates and high toxicities with the different regimens. Here, we report the case of 64-year-old man with metastatic medullary thyroid carcinoma in progression after primary treatment with cisplatin-doxorubicin. The patient received capecitabine 2000 mg/m total per day x 14 days followed by 1-week rest. He received 41 cycles, and presented prolonged and objective tumor response (30 months), without any toxicity.

PMID:
17581307
DOI:
10.1097/CAD.0b013e3280adc8f3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center